Source: Google NewsPublished on 2022-06-20
Related Articles:
- FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis April 8, 2021 The Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Acadia Pharmaceuticals regarding the supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis. The sNDA submission was supported by data from the pivotal phase 3 HARMONY study (ClinicalTrials.gov: NCT03325556) that compared the efficacy and safety of pimavanserin,…
- Nuplazid ‘Significantly’ Slows Relapses in Dementia-Related Psychosis, Phase 3 Trial Shows October 7, 2019 Interim results from the ongoing Phase 3 HARMONY study show that treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in patients with dementia-related disorders, such as Parkinson’s and Alzheimer’s disease. Evaluation by an independent data monitoring committee recommended an early stop to this placebo-controlled trial based on the treatment’s “robust” efficacy, Acadia Pharmaceuticals — Nuplazid’s manufacturer — announced in a…
- Benefits of Acadia’s Nuplazid Outweigh Risks for Parkinson’s Psychosis Patients, FDA Reports September 24, 2018 Nearly half a year after news reports surfaced about deaths allegedly linked to Nuplazid (pimavanserin) — a therapy for Parkinson’s patients with disease-related psychosis — the U.S. Food and Drug Administration says it could not find any new or unexpected safety concerns with the controversial treatment. The agency said in a Sept. 20 press release that “after a thorough review, the FDA’s…
- Psychosis Treatments October 28, 2019 Psychosis Treatments PSYCHOSIS TREATMENTS Generic Brand Form Indication Adult Initial Dose Adult Dose Titration First-Generation Antipsychotics chlorpromazine HCl — tabs Psychosis. Mania Less acutely disturbed: 25mg three times dailyOutpatient: 10mg 3–4 times daily or 25mg 2–3 times dailySevere cases: 25mg three times daily Inpatient: 500–1000mg/dayLess acutely disturbed: 400mg/dayOutpatient: 200–800mg/day Increase dose gradually until symptoms are controlled. Continue optimum dosage for…
- Nuplazid’s Risks in Treating Parkinson’s Psychosis Don’t Appear Exceptionally High, Experts Say June 11, 2018 The controversy surrounding Nuplazid (pimavanserin), Acadia Pharmaceuticals‘ approved treatment for psychosis in Parkinson’s patients, has made its way to scientific journals. But experts appear to take a more questioning view of the medication’s risks than that aired by general media. A clinical trial comparing the effectiveness and benefits of Nuplazid to other antipsychotics used to treat these patients would be warranted, and ideally…
- Psychosis in Parkinson’s Linked to Volume Changes in Specific Area of Brain, Study Says June 7, 2018 Psychosis and cognitive impairment in patients with Parkinson’s disease may be linked to structural changes in the brain, namely a decrease in volume of an area that controls memory formation, a study suggests. The study, “Hippocampal subfield atrophy in patients with Parkinson’s disease and psychosis,” was published in the Journal of Neural Transmission. Psychosis, which usually manifests as visual hallucinations,…
- Nuplazid and Clozaril Are Most Reliable Parkinson’s Psychosis Therapies, Review Finds March 7, 2018 The antipsychotics Nuplazid (pimavanserin) and Clozaril (clozapine) are the only therapies shown to improve Parkinson’s disease psychosis (PDP) symptoms without impairing motor function, in double-blind, placebo-controlled clinical trials, according to a review. The study, “Pharmacological interventions for psychosis in Parkinson’s disease patients,” was published in the journal Expert Opinion on Pharmacotherapy. Parkinson’s disease psychosis is a non-motor symptom that causes patients to experience hallucinations…
- How to Bring Light to the Darker Side of Parkinson’s: A Primer on Hallucinations and Delusions and How to Manage Them July 18, 2018 When most people think of Parkinson’s, they think of the motor symptoms that often come with it: tremor, rigidity, slowness, shuffling. However, they are often unaware that Parkinson’s comes with a wide variety of non-motor symptoms that can affect thinking, mood and behavior as well. Parkinson’s disease psychosis is a non-motor symptom of Parkinson’s that causes people to experience hallucinations…
- New Phase 3 Trial to Test Nuplazid for Parkinson’s Psychosis in Array of Dementia Patients October 5, 2017 Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Pimavanserin, under the brand name Nuplazid, was approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis in Parkinson’s patients in 2016. This trial, and the Breakthrough…
- Faith, Medical Science & the FDA June 28, 2021 I’ve never been devout. I was raised in a secular Jewish home. For my parents being Jewish meant a connection to a people, not to any creed or book. I owe my life to that distinction. Most of my great grandparents were devoutly religious. When the Nazis occupied Poland in 1939 their children, my grandparents, saw the writing on the…
- Once-a-day Capsule for Nuplazid and Lower Dose Option Approved for Parkinson’s Psychosis Patients July 2, 2018 The U.S. Food and Drug Administration has approved a once-a-day capsule formulation and a lower tablet strength for Nuplazid (pimavanserin), a treatment for the hallucinations and delusions associated with Parkinson’s psychosis. The new formulation — a 34 mg capsule— enables patients to take the recommended oral dose once a day instead of the twice-daily existing 17-mg tablet dose. Also approved…
- FDA Rejects Nuplazid for Alzheimer's, Other Dementia-related Psychosis - Alzheimer's News Today April 5, 2021 FDA Rejects Nuplazid for Alzheimer's, Other Dementia-related Psychosis Alzheimer's News Today
- Nuplazid Shows Sustained Easing of Psychosis in Patients in Phase 3 Trial June 8, 2020 Daily use of Nuplazid (pimavanserin) leads to strong and sustained reductions in the frequency and severity of hallucinations and delusions in people with Parkinson’s disease psychosis, according to data from a long-term extension study. These findings, “Improvement and Durability in SAPS-PD Assessment over 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis,” were presented at the at the 2020 American…
- Depression and Psychosis Are Markers of More Severe Disease, Database Study Says July 30, 2019 Mental illness in people with Parkinson’s disease, more frequently found in female and older patients, appears to associate with more severe disease, a new study reports. Titled, “Comorbid Depression and Psychosis in Parkinson’s Disease: A Report of 62,783 Hospitalizations in the United States,” the study was published in the journal Cureus. Although Parkinson’s disease is best known for its motor symptoms,…
- Long-term Nuplazid Safe, Well-tolerated by Parkinson’s Psychosis Patients, Extension Study Shows June 5, 2020 Nuplazid (pimavanserin), an approved therapy for treating hallucinations associated with Parkinson’s disease psychosis, is generally safe and well-tolerated in the long run, and may be associated with reduced mortality in this particular patient population, findings from a long-term extension study suggest. The results were presented at the 2020 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, which was held virtually due…
- Long-term Nuplazid Safe, Well-tolerated by Parkinson’s Psychosis Patients, Extension Study Shows June 5, 2020 Nuplazid (pimavanserin), an approved therapy for treating hallucinations associated with Parkinson’s disease psychosis, is generally safe and well-tolerated in the long run, and may be associated with reduced mortality in this particular patient population, findings from a long-term extension study suggest. The results were presented at the 2020 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, which was held virtually due…
- EMA rejects FDA-approved Parkinson's drug, signs off on Moderna vaccine use in adolescents ahead of FDA - Endpoints News July 22, 2021 EMA rejects FDA-approved Parkinson's drug, signs off on Moderna vaccine use in adolescents ahead of FDA Endpoints News
- Nuplazid’s Mortality Risk Not Different from Seroquel, Combo Treatment, Study Finds September 28, 2018 Treatment with Nuplazid (pimavanserin) does not lead to a different mortality risk compared to the antipsychotic medication Seroquel (quetiapine), or to combination treatment with both medications, in patients with Parkinson’s psychosis, according to results from a large study. The study, “Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine” was published in the journal Neurology. In April 2016, Acadia…
- Increased risk of falls and fractures in patients with psychosis and Parkinson disease. January 28, 2021 Related ArticlesIncreased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021;16(1):e0246121 Authors: Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G Abstract OBJECTIVE: Evaluate whether the risk of falls and fractures differs between patients with Parkinson disease with psychosis (PDP) and patients with Parkinson disease (PD) without…
- Treatment with Stalevo and Comtan Does Not Raise Prostate Cancer Risk, FDA Finds August 22, 2019 A review by the U.S. Food and Drug Administration (FDA) found that Parkinson’s patients treated with medications containing entacapone are at no increased risk of prostate cancer. As such, the agency stands by its current recommendations for the use of Stalevo (entacapone/carbidopa/levodopa) and Comtan (entacapone; brand name is Comtess elsewhere) to ease motor problems in Parkinson’s disease. The FDA review was conducted after the findings…
- Recon: PTAB Rejects Bid to Challenge Celgene's Revlimid Patent - Regulatory Focus March 14, 2019 Recon: PTAB Rejects Bid to Challenge Celgene's Revlimid Patent Regulatory FocusWelcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. US court rejects Alvogen's patent challenge for ...
- FDA Continuing to Monitor Nuplazid Use, Agency Says in Response to Controversial CNN Report April 16, 2018 The U.S. Food and Drug Administration is keeping close watch on the use of Nuplazid (pimavanserin) by Parkinson’s patients with disease-related psychosis, but at present sees no reasons to change the existing warnings placed on the medication — sold by Acadia Pharmaceuticals — when first approved. The FDA stated its position, given in response to a recent CNN report on patient…